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www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMballoon and stent (BS), and atherectomy and balloon (AB) (B-29%, BS-27%, and AB-
31%). In repeat PVI, B and BS use were different from the initial PVI (B 39%, BS
17%, respectively p< 0.001), and AB use was not different (34%, p¼0.2). A network
plot of device use and change from initial to repeat procedure is shown (p< 0.001 for
pattern).Conclusions: In a contemporary PAD patient population, multiple PVI procedures
occur commonly, but the majority are procedures in a different vascular bed. Repeat
PVI in the same vessel occurs less often. Balloon angioplasty remains the dominant
procedure for both the initial or repeat LE PVI, either as stand-alone therapy or in
combination with stent or atherectomy.
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Background: Peripheral endovascular intervention (PVI) has changed the treat-
ment landscape for patients with PAD. The primary aim of this analysis is to
understand the trends and variation in PVI after changes in Medicare Coverage
Determination (MCD) in 2008 that affect professional and technical reimbursement
rates for PVI.
Methods: We utilized a 5% sample of Medicare beneﬁciaries from 2006 to 2011, and
patients were required to have a procedure code for revascularization and a diagnosis
code for PAD. Rates of revascularization were age- and sex-adjusted to the Medicare
fee-for-service population. Rates by treatment location, year, and physician specialty
were reported per 100,000 beneﬁciaries.
Results: 39,339 patients underwent revascularization for PAD and were included in
the analysis. The PVI rate increased from 4,986 in 2006 to 5,548 in 2011, while the
rate of surgical revascularization decreased from 1,562 in 2006 to 1,172 in 2011
[Panel A]. Surgeons (50%) and cardiologists (33%) performed the majority of PVI
[Panel B]. The rate of PVI performed in inpatient settings declined signiﬁcantly while
the rate of PVI performed in outpatient hospital settings and ofﬁce-based clinics
increased signiﬁcantly [Panel C]. The use of atherectomy increased 50-fold in ofﬁce-
based clinics since 2006.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/IliaConclusions: The overall rates of PVI increased by 10%, mostly performed by
surgeons and cardiologists. PVI and especially atherectomy use in outpatient set-
tings increased dramatically, highlighting possible unintended consequences of
coverage decisions and need for studies demonstrating beneﬁt for endovascular
technologies.
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Background: Endovascular approach to superﬁcial femoral artery (SFA) disease, the
most common cause of symptomatic PAD, remains fraught with high failure rates.
Newer devices including second-generation nitinol stents, drug-coated stents, drug-
coated balloons, covered stents, cryo-therapy, LASER and directional atherectomy,
have shown promising results. Clinical equipoise still persists regarding the optimal
selection of devices, largely attributable to the different inclusion criteria, study
population, length of lesions treated, deﬁnition of “patency” and “restenosis” and
follow-up methods in the pivotal trials.
Methods: A prospective protocol was developed. We performed a literature search
using PubMed from January 2006 – November 2013. Published articles including
endovascular interventions in SFA or popliteal arteries with reported 12-month “pri-
mary patency” or “binary restenosis” rates as endpoints were included.
Results: We identiﬁed 6024 patients in 61 trials reporting 12-month primary patency
rates in patients with femoropoliteal disease. Primary patency rates were (weighted
average) 78% for nitinol stents, 68.8% for Covered stents, 84% for Drug eluting
stents, 78.2% for DEB, 60.7% for cryoballoon, 51.1% for LASER atherectomy,
63.5% for directional atherectomy and 70.2% with a combination of endovascular
devices.
Conclusions: The most frequently used endovascular devices yielded various
12-month primary patency rates ranging from 51% to 85%. The increased variation in
inclusion criteria, length and complexity of lesions between studies does not allow
direct comparison between them. Larger randomized trials in speciﬁc patient pop-
ulations comparing those modalities is needed before we can make safe recommen-
dation of the superiority of one device over the other.
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Background: Case series where the use of optical coherence tomography (OCT)
greatly reduced or eliminated ﬂuoroscopy during the crossing of peripheral arterial
chronic total occlusions (CTOs) when using the Ocelot catheter (Avinger Inc, CA).
Methods: Fifteen patients, with sixteen lesions (n¼16) were successfully treated for
peripheral arterial CTOs between January 2013 and June 2013. Ocelot imaging
identiﬁes arterial structures to guide catheter crossing within the true lumen. By
placing the middle marker over arterial structures, the catheter tip is deﬂected in the
opposite direction towards atheroma (Figure 1). Time measurements were recorded for
diagnostic angiography, CTO crossing ﬂuoroscopy, and therapeutic ﬂuoroscopy
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